Description_x000D_ Application_x000D_ Tetrabromocinnamic acid (TBCA) has been used in protein-fragment complementation assay, in an approach to identify inhibitors of αsyn oligomerization._x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Tetrabromocinnamic acid (TBCA) is a selective cell-permeable ATP-competitive casein kinase CK2 inhibitor with an IC50 of 110 nM, 2-fold selectivity over CK1, and with the advantage of being less active on DYRK1A (IC50 = 24.5 μM) than other CK2 inhibitors suh as DMAT. Elevated levels of CK2 are associated with many cancers and also with tau hyperphosphorylation and neuropathology found in Alzheimer′s disease and other neurodegenerative disorders. In prostate cancer cells TBCA reduced cell proliferation and caused G2/M cell cycle arrest. In isolated squid axoplasms, TBCA also blocked inhibition of fast axonal transport by Aβ oligomers.